Norikazu Masuda - Dissemin

Language
Login

All papers authored by Norikazu Masuda

This paper was not found in any repository, but could be made available legally by the author.

2022 Haruru Kotani

ORCID

, Norikazu Masuda

ORCID

, Toshinari Yamashita

ORCID

ORCID

, Tetsuhiko Taira

ORCID

, Kenichi Inoue

ORCID

, Masato Takahashi

ORCID

, Kan Yonemori, Shigeyuki Toyoizumi

ORCID

ORCID

, Takashi Nagasawa

ORCID

ORCID

, Hiroji Iwata

Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study

Upload

This paper is made freely available by the publisher.

Yutaka Yamamoto

ORCID

, Hiroji Iwata, Naruto Taira

ORCID

, Norikazu Masuda

ORCID

, Masato Takahashi

ORCID

, Tetsuhiro Yoshinami, Takayuki Ueno

ORCID

, Tatsuya Toyama

ORCID

, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura

ORCID

, Hiroshi Tada and 7 other authors

Pertuzumab retreatment for HER2 ‐positive advanced breast cancer: a randomized, open‐label phase III study ( PRECIOUS )

Download from onlinelibrary.wiley.com

This paper was not found in any repository, but could be made available legally by the author.

Norikazu Masuda

ORCID

, Makiko Ono, Toru Mukohara, Hiroyuki Yasojima, Tatsunori Shimoi, Kokoro Kobayashi, Kenichi Harano, Makiko Mizutani, Maki Tanioka

ORCID

, Shunji Takahashi, Takahiro Kogawa

ORCID

, Takuya Suzuki, Shiori Okumura, Takao Takase, Reiko Nagai and 4 other authors

Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort

Upload

This paper was not found in any repository, but could be made available legally by the author.

Dennis J. Slamon, Massimo Cristofanilli

ORCID

, Hope S. Rugo, Nicholas C. Turner, Rugo Hs, Seock-Ah Im

ORCID

, Im Sa, Slamon Dj, Nadia Harbeck

ORCID

, Igor Bondarenko

ORCID

, Norikazu Masuda

ORCID

, Marco Colleoni

ORCID

, Angela DeMichele, Sherene Loi

ORCID

ORCID

and 10 other authors

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Upload

This paper is made freely available by the publisher.

Takayuki Ueno

ORCID

, Shigehisa Kitano, Norikazu Masuda

ORCID

, Daiki Ikarashi, Makiko Yamashita, Tomohiro Chiba, Takayuki Kadoya, Hiroko Bando, Takashi Yamanaka, Shoichiro Ohtani, Shigenori Nagai, Takahiro Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi and 6 other authors

Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

Download from doi.org

This paper is made freely available by the publisher.

Norikazu Masuda

ORCID

, Yucherng Chen, Tsutomu Kawaguchi, Koji Dozono

ORCID

, Masakazu Toi

Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels

Download from doi.org

This paper is made freely available by the publisher.

2021 Norikazu Masuda

ORCID

, Kenji Tamura, Hiroyuki Yasojima, Akihiko Shimomura, Masataka Sawaki, Min-Jung Lee, Akira Yuno, Jane Trepel, Ryoko Kimura, Yozo Nishimura, Shigehira Saji, Hiroji Iwata

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Norikazu Masuda

ORCID

, Nobuyoshi Kosaka, Hiroji Iwata, Masakazu Toi

Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data

Upload

This paper is made freely available by the publisher.

Norikazu Masuda

ORCID

, Tetsuhiro Yoshinami, Masahiko Ikeda, Makiko Mizutani, Miki Yamaguchi, Yoshifumi Komoike

ORCID

, Tsutomu Takashima

ORCID

, Katsuhide Yoshidome

ORCID

, Junji Tsurutani

ORCID

, Mitsuhiko Iwamoto, Fumie Fujisawa

ORCID

, Hiroyuki Yasojima, Jun Yamamura

ORCID

, Hirotaka Morishima, Fuminori Aki and 3 other authors

Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Patrick Neven, Stephen R. D. Johnston, Masakazu Toi

ORCID

ORCID

, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda

ORCID

, Peter A. Kaufman, Han Koh, Eva-Maria Grischke, PierFranco Conte

ORCID

, Yi Lu

ORCID

, Nadine Haddad and 3 other authors

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer

Upload

This paper is made freely available by the publisher.

Eriko Tokunaga, Norikazu Masuda

ORCID

, Naohito Yamamoto, Hiroji Iwata, Hiroko Bando

ORCID

, Tomoyuki Aruga, Shoichiro Ohtani, Tomomi Fujisawa, Toshimi Takano, Kenichi Inoue, Nobuyasu Suganuma, Masahiro Takada, Kenjiro Aogi, Kenichi Sakurai, Hideo Shigematsu and 5 other authors

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Eva Maria Ciruelos, Hope S. Rugo

ORCID

, Ingrid A. Mayer

ORCID

, Christelle Levy, Frédéric Forget, Juan Ignacio Delgado Mingorance, Juan Ignacio Delgado Mingorance, Tamar Safra

ORCID

, Norikazu Masuda

ORCID

, Yeon Hee Park, Dejan Juric

ORCID

, Pierfranco Conte

ORCID

, Mario Campone, Sibylle Loibl

ORCID

ORCID

and 5 other authors

Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1

Upload

This paper is made freely available by the publisher.

Masakazu Toi

ORCID

, Kenichi Inoue, Norikazu Masuda

ORCID

, Hiroji Iwata, Joohyuk Sohn, P. Kellie Turner, In Hae Park

ORCID

, In Hae Park, Seock‐Ah Im, Shin‐Cheh Chen, Sotaro Enatsu, P. Kellie Turner, Valérie A. M. André, Molly C. Hardebeck, Sachi Sakaguchi and 2 other authors

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Manabu Futamura

ORCID

, Mari Oba

ORCID

, Norikazu Masuda

ORCID

, Hiroko Bando, Morihito Okada, Yutaka Yamamoto, Takanori Kin, Toshiaki Saeki, Takeshi Nagashima, Takashi Kuwayama, Uhi Toh, Akira Hirano, Masafumi Inokuchi, Kazuhiko Yamagami, Yutaka Mizuno and 4 other authors

Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study)

Upload

This paper was not found in any repository, but could be made available legally by the author.

Norikazu Masuda

ORCID

, Hiroko Bando, Takashi Yamanaka, Takayuki Kadoya, Masato Takahashi, Shigenori E. Nagai, Shoichiro Ohtani, Tomoyuki Aruga, Eiji Suzuki, Yuichiro Kikawa, Hiroyuki Yasojima, Hiroi Kasai, Hiroshi Ishiguro, Hidetaka Kawabata, Satoshi Morita and 5 other authors

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial

Upload

This paper was not found in any repository, but could be made available legally by the author.

2020 Shinji Ohno

ORCID

, Shigehira Saji, Norikazu Masuda

ORCID

, Hitoshi Tsuda, Futoshi Akiyama, Masafumi Kurosumi, Akihiko Shimomura, Nobuaki Sato, Shintaro Takao, Shozo Ohsumi, Yutaka Tokuda, Hideo Inaji, Toru Watanabe, Yasuo Ohashi

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil with CMF (N·SAS-BC 01 trial and CUBC trial)

Upload

This paper was not found in any repository, but could be made available legally by the author.

Yoko Otani, Kiyoshi Mori, Nozomi Morikawa, Makiko Mizutani, Hiroyuki Yasojima, Misato Masuyama, Masayuki Mano, Norikazu Masuda

ORCID

Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report

Upload

This paper is made freely available by the publisher.

Moe Tsuda, Hiroshi Ishiguro

ORCID

, Naoko Toriguchi, Norikazu Masuda

ORCID

, Hiroko Bando, Masahiro Ohgami, Masato Homma, Satoshi Morita, Naohito Yamamoto, Katsumasa Kuroi, Yasuhiro Yanagita, Toshimi Takano

ORCID

, Satoru Shimizu, Masakazu Toi

Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Norikazu Masuda

ORCID

, Hirofumi Mukai, Kenichi Inoue, Yoshiaki Rai, Shinji Ohno, Shoichiro Ohtani, Chikako Shimizu, Satoshi Hashigaki, Yasuaki Muramatsu, Yoshiko Umeyama, Hiroji Iwata, Masakazu Toi

Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3

Upload

This paper was not found in any repository, but could be made available legally by the author.

Masato Takahashi, Shoichiro Ohtani, Shigenori E. Nagai, Seiki Takashima, Miki Yamaguchi, Michiko Tsuneizumi, Yoshifumi Komoike, Tomofumi Osako, Yoshinori Ito, Masahiko Ikeda, Kazushige Ishida, Takahiro Nakayama, Tsutomu Takashima, Takashi Asakawa, Sho Matsumoto and 2 other authors

The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study

Upload

Missing publications? Search for publications with a matching author name.